Value of ultrasound-guided attenuation parameter in the quantitative assessment of hepatic steatosis

doi:10.3969/j.issn.1004-583X.2025.02.011

Abstract

Abstract:

Objective To explore the feasibility of ultrasound guided attenuation parameter (UGAP) in the quantitative detection of hepatic steatosis. Methods A total of 102 patients who underwent liver ultrasound examination in Affiliated Zhongshan Hospital of Dalian University from February 2024 to June 2024 were selected. UGAP, blood lipids and abdominal computed tomography (CT) findings were collected. The correlation of attenuation coefficient (AC) obtained by UGAP with triglycerides (TG), total cholesterol (TC) and body mass index (BMI) was analyzed. Results A total of 74 patients diagnosed with fatty liver disease were included in the study, including 30 mild cases, 18 moderate cases, and 26 severe cases, and 28 healthy subjects with normal imaging findings were selected as the control group. There were significant differences in the BMI, TG, TC, liver CT value, and liver CT/spleen CT ratio between the fatty liver group and the control group, but age was comparable. There was a significant difference in AC value between groups, so as that among the mild, moderate and severe subgroups. Conclusion UGAP has certain clinical application value in the non-invasive and quantitative evaluation of hepatic steatosis.

Key words: fatty liver, ultrasound guided attenuation parameter, quantitative assessment

CLC Number:

R575.5

Sun Ya, Yang Shuang. Value of ultrasound-guided attenuation parameter in the quantitative assessment of hepatic steatosis[J]. Clinical Focus, 2025, 40(2): 158-161.

Add to citation manager EndNote|Ris|BibTeX

URL: https://lchc.magtechjournal.com/EN/10.3969/j.issn.1004-583X.2025.02.011

https://lchc.magtechjournal.com/EN/Y2025/V40/I2/158

Figures/Tables 3

References 21

[1]	Lazarus J, Mark H, Anstee Q, et al. NAFLD consensus consortium. advancing the global public health agenda for NAFLD: A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1):60-78.
[2]	Rockey D, Caldwell S, Goodman Z, et al. American Association for the Study of Liver Diseases. Liver biopsy[J]. Hepatology, 2009, 49:1017-1044. doi: 10.1002/hep.22742 pmid: 19243014
[3]	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 实用肝脏病杂志, 2007, 10(1):1-3.
[4]	许耀珑, 赵佳欣, 杨立刚. 非酒精性脂肪性肝病流行现状及危险因素研究进展[J]. 中国全科医学, 2024, 27(30):3825-3834. doi: 10.12114/j.issn.1007-9572.2023.0893
[5]	Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J]. Hepatology, 2015, 61(5):1547-1554. doi: 10.1002/hep.27368 pmid: 25125077
[6]	Fujiwara Y, Kuroda H, Abe T, et al. The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease[J]. Ultrasound Med Biol, 2018, 44(11):2223-2232. doi: S0301-5629(18)30272-2 pmid: 30077415
[7]	Bende F, Sporea I, Sirli R, et al. Ultrasound-guided attenuation parameter (UGAP) for the quantification of liver steatosis using the controlled attenuation parameter (CAP) as the reference method[J]. Med Ultrason, 2021, 23(1): 7-14. doi: 10.11152/mu-2688 pmid: 33220028
[8]	柯坚. 人体组织超声衰减成像新技术[J]. 中国超声医学杂志, 2000, (10):4-8.
[9]	Tada T, Kumada T, Toyoda H, et al. Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: Comparison with MRI-determined proton density fat fraction[J]. AJR Am J Roentgenol, 2019, 212(2):332-341.
[10]	Zhao Y, Jia M, Zhang C, et al. Reproducibility of ultrasound-guided attenuation parameter (UGAP) to the noninvasive evaluation of hepatic steatosis[J]. Sci Rep, 2022, 12(1):2876. doi: 10.1038/s41598-022-06879-0 pmid: 35190618
[11]	于晶晶. 肝功能和血脂及血糖水平联合检测在非酒精性脂肪肝患者病情评估中的应用价值[J]. 临床医药实践, 2020, 29(6):437-439.
[12]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5):947-957.
[13]	张姝嫔, 程成, 祝怡婕, 等. 超声衰减成像定量诊断非酒精性脂肪肝的应用价值初探讨[J]. 中国超声医学杂志, 2021, 37(1):66-69.
[14]	Iwashita H, Shakado S, Yoshimaru N, et al. Clinical utility of ultrasound-guided attenuation parameter for the detection and quantification of hepatic steatosis in patients with fatty liver diagnosed by computed tomography[J]. Ultrasound Med Biol, 2022, 48(7):1282-1289. doi: 10.1016/j.ultrasmedbio.2022.02.023 pmid: 35397929
[15]	Kodama Y, Ng CS, Wu TT, et al. Comparison of CT methods for determining the fat content of the liver[J]. AJR Am J Roentgenol, 2007, 188(5):1307-1312.
[16]	惠斌. CT在脂肪肝定量诊断中的应用价值分析[J]. 影像研究与医学应用, 2017, 1(11):131-132.
[17]	European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1):237-264. doi: 10.1016/j.jhep.2015.04.006 pmid: 25911335
[18]	Kumada T, Ogawa S, Goto T, et al. Intra-individual comparisons of the ultrasound-guided attenuation parameter and the magnetic resonance imaging-based proton density fat fraction using bias and precision statistics[J]. Ultrasound Med Biol, 2022, 48(8):1537-1546.
[19]	Kuroda H, Fujiwara Y, Abe T, et al. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis[J]. PLoS One, 2021, 16(4):e0249493.
[20]	Kumada T, Toyoda H, Yasuda S, et al. Liver stiffness measurements by 2D shear-wave elastography: Effect of steatosis on fibrosis evaluation[J]. AJR Am J Roentgenol, 2022, 219(4):604-612.
[21]	Kang K, Lee S, Jun D, et al. Diagnostic performance of a novel ultrasound-based quantitative method to assess liver steatosis in histologically identified nonalcoholic fatty liver disease[J]. Med Ultrason, 2023, 25(1):7-13. doi: 10.11152/mu-3815 pmid: 36780603

组别	例数	BMI(kg/m²)	TC(mmol/L)	TG(mmol/L)	肝脏CT值(HU)	肝脾CT比值
健康对照组	28	21.07±2.59	4.16±1.00	1.21±0.76	60.46±5.05	1.28±0.10
脂肪肝组	74	26.30±3.30	4.88±1.33	2.12±1.40	47.68±10.08	0.99±0.20
t值		1.944	2.312	2.765	16.107	9.206
P值		<0.01	<0.01	<0.01	<0.01	<0.01

组别	例数	BMI(kg/m²)	TC(mmol/L)	TG(mmol/L)	肝脏CT值(HU)	肝脾CT比值
健康对照组	28	21.07±2.59	4.16±1.00	1.21±0.76	60.46±5.05	1.28±0.10
脂肪肝组	74	26.30±3.30	4.88±1.33	2.12±1.40	47.68±10.08	0.99±0.20
t值		1.944	2.312	2.765	16.107	9.206
P值		<0.01	<0.01	<0.01	<0.01	<0.01

组别	例数	AC值(dB·cm^-1·MHz^-1)
健康对照组	28	0.50±0.06
脂肪肝组	74	0.69±0.08
轻度	30	0.61±0.04
中度	18	0.70±0.04
重度	26	0.78±0.03
F值		206.062
P值		<0.01

组别	例数	AC值(dB·cm^-1·MHz^-1)
健康对照组	28	0.50±0.06
脂肪肝组	74	0.69±0.08
轻度	30	0.61±0.04
中度	18	0.70±0.04
重度	26	0.78±0.03
F值		206.062
P值		<0.01